All the necessary information including the data used for this study is available in the Supporting Information files.

Introduction {#sec005}
============

Evidence-based laboratory medicine is an essential part of modern laboratory medicine practices \[[@pone.0201782.ref001]\]. It is estimated that clinical laboratory data influence 70% of clinical decisions; often providing pivotal information for physicians, nurses, public health officers, and other healthcare providers in the prevention, diagnosis, treatment and management of disease \[[@pone.0201782.ref002]\]. Technological advancement and economic driving forces have led to major changes in clinical laboratories globally, primarily represented by an increase in testing productivity and efficiency \[[@pone.0201782.ref003]\].

In the clinical laboratory, reference interval (RI) is the interval between, and including, two reference limits. It is the most widely used medical decision-making tool that separates healthy from diseased individuals. Clinicians compare the values of laboratory reports with the given RIs to make a decision regarding the health status of a given individual in clinical diagnosis, treatment and therapeutic monitoring. Therefore, accurate and reliable RI is an integral part of the process of correct interpretation of clinical laboratory test results for patient care \[[@pone.0201782.ref004]--[@pone.0201782.ref009]\].

International guidelines recommend that RIs are needed for all tests in the clinical laboratory. Clinical laboratories and diagnostic test manufacturers should establish their own RIs for healthy individuals belonging to a group of homogenous population \[[@pone.0201782.ref010]\]. However, the majority of clinical laboratories in the world adopt RIs established by manufacturers, rather than developing their own or verifying the applicability of those RIs to their specific population \[[@pone.0201782.ref011]\]. International organizations also recommend that population-specific clinical laboratory RIs should be established because gender, age, ethnicity, race, diet, geographical location and other factors could affect the physiological value of biochemical parameters \[[@pone.0201782.ref012]\].

For many African population, the clinical laboratory RIs have not been established, and non-locally derived RIs are usually being used in diagnostic laboratories and clinical trials to screen, diagnose and monitor disease conditions \[[@pone.0201782.ref013]\]. In Ethiopia, health facilities are dependent on RIs published either in available textbooks or diagnostic kit inserts. Given the dietary habits, geographical location and ethnic diversity as a source of variability, it is necessary to establish population-specific RIs for Ethiopian population. Therefore, the aim of this study was to establish RIs for routine clinical chemistry parameters among healthy adults in Amhara National Regional State, Ethiopia.

Materials and methods {#sec006}
=====================

Study design, period, and setting {#sec007}
---------------------------------

A multicenter cross-sectional study was conducted among blood donors in Amhara National Regional State, Ethiopia from March 2016 to May 2017. The Amhara National Regional State ([Fig 1](#pone.0201782.g001){ref-type="fig"}) extends from 9° to 13° 45\' N and 36° to 40° 30\'E. The altitude ranges from 500--4,620 meters above sea level. Based on the 2007 national census report of Central Statistical Agency of Ethiopia, the region has a total population of 17,221,976 (8,641,580 men and 8,580,396 women). The region consists 11 zones, 139 weredas (districts) and 3422 kebeles (neighborhoods) (348 urban and 3074 rural). Amhara (91.5%), Agew-Awi (3.5%), Oromo (2.6%) and Agew Hamyra (1.4%) are the top ranking ethnic groups found in the region. Majority (82.5%) of people living in the region are Orthodox Christians followed by Muslims (17.2%), Protestants (0.2%), Traditional believers (0.03%) and Catholics (0.02%) \[[@pone.0201782.ref014]\].

![Map of the study area.](pone.0201782.g001){#pone.0201782.g001}

Bahir Dar is the capital city of the region, and it is located 560 Kilometers away from Addis Ababa, the capital city of Ethiopia. It has an altitude of 1800 meters above sea level with a total population of 221,991. Debre Markos tow is located 270 Kilometers away from Bahir Dar city. It has an altitude of 2,446 meters above sea level with a total population of 62,497. Gondar town is located 175 Kilometers far from Bahir Dar city. It has an altitude of 2,133 meters above sea level with a total population of 207,044. Dessie town is located 480 Kilometers away from Bahir Dar city. It has an altitude of 2,470 meters above sea level with a total population of 151,174. The study included those participants who were living in and around the aforementioned four areas where ethnic, socio-economic, socio-demographic and altitude differences are not significant among the respective populations \[[@pone.0201782.ref014]\].

Reference population {#sec008}
--------------------

This study included apparently healthy young adults who were selected at each blood donation centre. Disease history questionnaire, physical examination and infectious disease screening tests were used to selected eligible study participants. Adults (age: 18--60 years) with normal body mass index (18--25 kg/m^2^) were candidates of this study. Whereas, adults with known disease like, diabetes mellitus, chronic renal insufficiency, hypertension, ischemic heart disease, anemia, thyroid disease and liver diseases were excluded. Moreover, adults who were taking medications, chronic alcohol abusers, smokers, pregnant and lactating women, positive for transfusion transmissible infections (human immune deficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis), and who had a history of jaundice within 3 months and major surgery within 1 year were excluded from the study \[[@pone.0201782.ref010]\].

Sample size and sampling technique {#sec009}
----------------------------------

The Clinical Laboratory Standards Institute/International Federation for Clinical Chemistry (CLSI/IFCC) recommended non-parametric methods to establish Rls \[[@pone.0201782.ref010]\]. In order to estimate a non-parametric 95% RI with 95% confidence interval, a minimum of 120 reference individuals are needed per partition (female and male, in our case). From the six blood banks in Amhara National Regional State, four were selected systematically considering their geographical location and population homogeneity. A total of 22 blood donation centres were included in those four blood banks. Then, the reference individuals were recruited by convenient sampling technique at each blood donation centre. More than 120 adults were included per partition because some of them were expected to be excluded by infectious disease screening. A total of 1,290 participants were screened and reviewed at four blood banks of which 1,175 study participants who met the inclusion criteria were selected for this study.

Data collection and laboratory analysis {#sec010}
---------------------------------------

Data collectors were trained for three days about the objective of the study, study participants' rights, confidentiality of patient information, procedure of physical examination, procedure of blood sample collection and measurements, and how to approach and interview participants before the actual data collection. The study participants were contacted when they came to the blood donation centres for donation. Study participants who agreed to give written consent after being informed about the purpose of the study and associated risks were physically examined and interviewed. Socio-demographic data and blood sample were collected from those blood donors who fulfilled the criteria set to say apparently healthy.

About 5 ml of blood sample was collected from each study participant using plane tube. The sample was centrifuged at 2500 rpm (revolution per minute) for 5 minutes to separate serum. Then, the serum sample was tested for HIV, HBV, HCV and Syphilis at each blood bank. Sero-negative serum sample was stored at -20°~C~ until analysis. Finally, the sample was transported to Amhara Public Health Institute (APHI) for analysis. Mindray BS-200E (Shenzhen Mindray Bio-medical electronics co.ltd, China) full automated clinical chemistry analyzer was used for the measurement of biochemical analytes. HUMAN (HUMAN diagnostics, Germany) reagents including control samples and calibrator were used for all clinical chemistry parameters determination.

Clinical chemistry parameters were determined by the methods/techniques described as follows: Alanine aminotransferase and aspartate aminotransferase by kinetic (IFCC without pyridoxalphosphate activation); alkaline phosphatase (ALP) by optimized standard method of DGKC (DEA buffer); gamma-glutamyl transferase (GGT) by L-gamma-glutamyl-3-carboxy-4-nitranilide; amylase by CNP (2-chloro-4-nitrophenol); creatinine by Jaffe (kinetic, without deprotinisation); urea by kinetic urease/GLDH (Glutamate dehydrogenase); uric acid by uricase-PAP (4-aminophenazone); total cholesterol by CHOD-PAP (cholesterol peroxidase- 4-aminophenazone); triglycerides by G-PAP (Glycerol -3-phosphate oxidase- 4-aminophenazone); total protein by biuret; albumin by bromocresol green; and direct bilirubin and total bilirubin by DPD (3,5-dichlorophnyl-diazonium-tetrafloroborate) methods. The viral infectious diseases (HIV, HBV and HCV), and syphilis were screened by enzyme-linked immunosorbent assay (ELISA) and rapid plasma reagin (RPR) techniques, respectively.

Laboratory data quality management {#sec011}
----------------------------------

All pre-analytical, analytical and post-analytical phases of quality assurance cycle were managed based on standard precautions. Each activity including blood sample collection, transportation, storage and analysis was based on good laboratory practices (GLP) using standard operating procedures (SOPs) to ensure data quality. The analysis was done in APHI clinical chemistry laboratory which is closely supervised by Ethiopian Public Health Institute (EPHI). The equipment had been calibrated monthly by type-Autocal. In addition, two levels (normal and pathological) of internal quality control (IQC) samples were run along with the serum sample. The control sample results were interpreted using Westgard multi-rule algorithm. The control sample results had to be within acceptable ranges prior serum sample testing. Moreover, the laboratory had been participating in external quality assessment programs like an onsite evaluation by EPHI and international digital proficiency testing by One World Accuracy three times per year.

Data analysis and interpretation {#sec012}
--------------------------------

Data were cleared, edited, checked for completeness manually and entered to EPI Info version 3.5.3 (CDC, USA) statistical software, and then transferred to SPSS version 20 (IBM, USA) software for analysis. Kolmogorov--Sminorv test was used to check data distribution normality. Wilcoxon rank-sum test was also used to see whether partition was needed between males and females. RIs were calculated in accordance with CLSI/IFCC guideline using non-parametric methods \[[@pone.0201782.ref010]\]. The 95% RIs were estimated using reference limits at 2.5^th^ percentile for the lower reference limit and 97.5^th^percentile for the upper reference limit.

Ethical consideration {#sec013}
---------------------

The study was conducted after ethical approval was obtained from Research and Ethics Institutional Review Board of the University of Gondar. Informed written consent was also obtained from each study participant before the actual data collection. Individuals positive for transfusion-transmissible infections and other disease conditions were linked to nearby government hospitals for further diagnosis and treatment accordingly.

Results {#sec014}
=======

Socio-demographic characteristics {#sec015}
---------------------------------

A total of 1,175 apparently healthy young adults were recruited to establish the RI of clinical chemistry parameters from four blood banks in Amhara National Regional State, Ethiopia. Out of all study participants, 644 (54.8%) were males. The study participants' median (IQR) age was 20 (18--22) year. About 706 (60.1%), 977 (83.1%) and 1,075 (91.5%) of the study participants were aged 18--20 years old, students and single, respectively ([Table 1](#pone.0201782.t001){ref-type="table"}).

10.1371/journal.pone.0201782.t001

###### Socio-demographic characteristics of blood donors in Amhara National Regional State blood banks, Ethiopia, 2017 (n = 1,175).

![](pone.0201782.t001){#pone.0201782.t001g}

  Variables            Blood banks                Total                                  
  -------------------- ------------- ------------ ------------ ------------ ------------ -------------
  **Sex**              Male          176(15.0%)   158(13.4%)   144(12.3%)   166(14.1%)   644(54.8%)
  Female               127(10.8%)    135(11.5%    132(11.2%)   137(11.7%)   531(45.2%)   
  **Age**              18--20        277(23.6%)   196(16.7%)   137(11.7%)   96(8.2%)     706(60.1%)
  21--29               19(1.6%)      92(7.8%)     131(11.1%)   159(13.5%)   401(34.1%)   
  30--39               5(0.4%)       5(0.4%)      7(0.6%)      31(2.6%)     48(4.1%)     
  40--61               2(0.2%)       0(0.0%)      1(0.1%)      17(1.4%)     20(1.7%)     
  **Marital status**   Single        293(24.9%)   288(24.5%)   263(22.4%)   231(19.7%)   1075(91.5%)
  Married              10(0.9%)      5(0.4%)      13(1.1%)     72(6.1%)     100(8.5%)    
  **Occupation**       Student       292(24.9%)   257(21.9)    254(21.6%)   174(14.8%)   977(83.1%)
  Employed             11(0.9%)      34(2.9%)     13(1.1%)     67(5.7%)     125(10.6%)   
  Other                0(0.0%)       2(0.2%)      9(0.8%)      62(5.3%)     73(6.2%)     
  **Total**            303(25.8%)    293(24.9%)   276(23.5%)   303(25.8%)   1175(100%)   

**%**: percent, **N**: number.

Reference intervals of clinical chemistry parameters {#sec016}
----------------------------------------------------

We observed statistically significant differences between males and females in clinical chemistry parameters' RIs. Except total cholesterol, all clinical chemistry parameter values were higher in males than females ([Table 2](#pone.0201782.t002){ref-type="table"}).

10.1371/journal.pone.0201782.t002

###### The RIs of clinical chemistry parameters among blood donors in Amhara National Regional State, Ethiopia, 2017 (N = 1,175; Male = 644, and Female = 531).
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analytes                  Unit     Sex             Mean     95% CI of Mean   Median          25^th^--75^th^ percentile   2.5^th^--97.5^th^ percentile, RI   p-value[\*](#t002fn001){ref-type="table-fn"}
  ------------------------- -------- --------------- -------- ---------------- --------------- --------------------------- ---------------------------------- ----------------------------------------------
  **ALT/SGPT**              U/L      Combined        15.71    15.22,16.24      14.0            10.0,19.0                   5.0--39.0                          \<0.0001

  Male                      17.15    16.50,17.88     15.0     12.0,20.0        5.13--42.88                                                                    

  Female                    13.97    13.34,14.74     12.0     9.0,16.0         4.3--37.0                                                                      

  **AST/SGOT**              U/L      Combined        22.84    22.35,23.36      21.0            17.0,27.0                   11.0--46.0                         \<0.001

  Male                      24.13    23.46--24.77    23.0     19.0,28.0        12.13--46.88                                                                   

  Female                    21.27    20.55,22.04     19.0     16.0,24.0        10.0--43.8                                                                     

  **ALP**                   U/L\     Combined        199.5    194.13,205.24    174.0           141.75,230.0                87.0--451.28                       \<0.0001

  Male                      217.55   209.09,225.91   186.0    147.0,269.0      77.20--475.8                                                                   

  Female                    177.56   171.28,184.07   162.0    134.0,204.0      89.0--381.0                                                                    

  **Amylase**\              U/L\     Combined        124.84   120.64,128.98    109.0           66.0,172.0                  29.0--299.0                        \<0.0001

  Male                      131.07   125.45,136.91   121.5    69.0,179.75      29.0--309.8                                                                    

  Female                    117.29   111.34,123.32   102.0    61.0,167.0       29.0--287.9                                                                    

  **GGT**                   U/L      Combined        18.39    17.63,19.15      15.0            11.0,21.0                   7.0--58.0                          \<0.0001

  Male                      21.08    20.06,22.27     17.0     13.0,24.0        7.0--69.8                                                                      

  Female                    15.13    14.34,15.97     13.0     10.0,17.0        6.0--39.1                                                                      

  **Bilirubin (direct)**\   mg/dl\   Combined        0.22     0.21,0.22        0.19            0.13,0.26                   0.02--0.61                         \<0.0001

  Male                      0.25     0.23,0.26       0.21     0.15,0.3         0.04--0.68                                                                     

  Female                    0.18     0.17,0.19       0.17     0.11,0.23        0.01--0.49                                                                     

  **Bilirubin (total)**\    mg/dl\   Combined        0.35     0.34,0.37        0.29            0.21,0.42                   0.1--1.1                           \<0.0001

  Male                      0.40     0.38,0.42       0.33     0.24,0.46        0.11--1.18                                                                     

  Female                    0.30     0.28,0.32       0.25     0.18,0.35        0.08--0.91                                                                     

  **Total protein**\        mg/dl\   Combined        7.59     7.52,7.65        7.5             6.8,8.3                     5.7--9.6                           \<0.0001

  Male                      7.70     7.61,7.78       7.7      6.9,8.5          5.7--9.7                                                                       

  Female                    7.45     7.37,7.54       7.4      6.7,8.2          5.6--9.47                                                                      

  **Albumin**\              g/dl\    Combined        5.0      4.97,5.04        5.0             4.6,5.4                     3.7--6.2                           \<0.0001

  Male                      5.08     5.03,5.13       5.1      4.6,5.5          3.7--6.2                                                                       

  Female                    4.9      4.86,4.95       5.0      4.5,5.3          3.6--6.1                                                                       

  **Total cholesterol**\    mg/dl    Combined        134.73   132.92,136.56    132.0           113.0,154                   80.4--206.6                        \<0.0001

  Male                      132.79   130.39,135.31   130.0    111.0,150.0      78.13--211.75                                                                  

  Female                    137.08   134.41,139.71   135.0    115.0,159.0      83.6--202.7                                                                    

  **Triglycerides**         mg/dl\   Combined        96.97    94.28,99.80      86.0            61.0,122.0                  36.0--215.6                        \<0.0001

  Male                      101.41   97.80,105.00    90.0     63.25,128.75     36.0--221.9                                                                    

  Female                    91.59    87.61,95.20     80.0     58.0,115.0       35.3--201.5                                                                    

  **Creatinine**\           mg/dl\   Combined        0.79     0.78,0.80        0.79            0.7,0.88                    0.47--1.12                         \<0.001

  Male                      0.83     0.82,0.84       0.83     0.75,0.92        0.48--1.13                                                                     

  Female                    0.75     0.74,0.76       0.74     0.66,0.82        0.47--1.09                                                                     

  **Urea**\                 mg/dl\   Combined        23.35    22.91,23.78      23.0            18.0,28.0                   11.0--41.0                         \<0.0001

  Male                      24.53    23.95,25.17     24.0     19.0,29.0        12.0--43.0                                                                     

  Female                    21.92    21.28,22.51     21.0     17.0,26.0        10.0--38.7                                                                     

  **Uric acid**\            mg/dl\   Combined        4.16     4.10,4.23        4.0             3.3,4.9                     2.34--6.60                         \<0.0001

  Male                      4.55     4.47,4.63       4.4      3.8,5.2          2.7--6.9                                                                       

  Female                    3.68     3.60,3.76       3.5      3.1,4.2          2.1--5.9                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*P-value: Wilcoxon rank-sum test for male versus female; **ALT**: Alanine aminotransferase; **ALP**: Alkaline phosphatase; **AST**: Aspartate aminotransferase; **CI**: confidence interval; **dl**: Decilitre; **g**: Gram; **GGT**: Gamma glutamyltransferase; **L**: litre; **mg**: Milligram; **RI**: Reference interval; **SGOT**: Serum glutamate oxaloacetate transaminase; **SGPT**: Serum glutamate pyruvate transaminase; **U**: Unit.

Confidence intervals for reference limits {#sec017}
-----------------------------------------

The 90% CI of lower and upper reference limits of established RIs of clinical chemistry parameters are calculated and presented in the table below. [Table 3](#pone.0201782.t003){ref-type="table"} showed that almost all lower reference limits have narrow 90% CI than upper reference limits.

10.1371/journal.pone.0201782.t003

###### The 90% CI of reference limits of clinical chemistry parameters RIs among blood donors in Amhara National Regional State, Ethiopia, 2017 (N = 1,175; Male = 644 and Female = 531).
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  ---------------------------------------------------------------------------------------------------------------------------------------------
  Analytes                 Unit          Sex             Range         2.5^th^--97.5^th^ percentile, RI   90% CI (lower\     90% CI (upper\
                                                                                                          reference limit)   reference limit)
  ------------------------ ------------- --------------- ------------- ---------------------------------- ------------------ ------------------
  **ALT/SGPT**             U/L           Combined        2.0--62.0     5.0--39.0                          4.0,5.0            36.0,45.0

  Male                     3.0--60.0     5.13--42.88     5.0,6.0       36.58,48.57                                           

  Female                   2.0--62.0     4.3--37.0       4.0,5.0       32.7,42.61                                            

  **AST/SGOT**             U/L           Combined        4.0--64.0     11.0--46.0                         10.0,11.4          42.2,49.0

  Male                     4.0--63.0     12.13--46.88    12.0,13.0     43.0,51.0                                             

  Female                   8.0--64.0     10.0--43.8      10.0,11.0     39.0,49.0                                             

  **ALP**                  U/L\          Combined        10.0--583.0   87.0--451.28                       74.75,93.0         433.0,474.0

  Male                     10.0--583.0   77.2--475.8     53.0,97.72    453.0,495.48                                          

  Female                   34.0--575.0   89.0--381.0     80.11,93.8    334.41,403.0                                          

  **Amylase**              U/L           Combined        10.0--367.0   29.0--299.0                        26.4,32.0          286.0,310.0

  Male                     10.0--367.0   29.0--309.8     25.8,32.0     289.55,317.38                                         

  Female                   10.0--357.0   29.0--287.9     24.2,33.0     254.0,302.38                                          

  **GGT**                  U/L           Combined        1.0--96.0     7.0--58.0                          6.0,7.0            53.0,67.0

  Male                     1.0--96.0     7.0--69.8       7.0,8.0       57.65,76.0                                            

  Female                   4.0--89.0     6.0--39.1       6.0,7.0       31.48,49.73                                           

  **Bilirubin (direct)**   mg/dl\        Combined        0.0--0.85     0.02--0.61                         0.01,0.04          0.53,0.66

  Male                     0.0--0.85     0.04--0.68      0.02,0.06     0.6,0.71                                              

  Female                   0.0--0.85     0.01--0.49      0.0,0.02      0.41,0.59                                             

  **Bilirubin (total)**    mg/dl\        Combined        0.02--1.89    0.1--1.1                           0.08,0.10          0.97,1.18

  Male                     0.02--1.89    0.11--1.18      0.09,0.13     1.1,1.28                                              

  Female                   0.05--1.39    0.08--0.91      0.73,0.1      0.78,1.04                                             

  **Total protein**\       mg/dl\        Combined        4.4--10.9     5.7--9.6                           5.6,5.8            9.5,9.7

  Male                     4.4--10.9     5.7--9.7        5.6,5.9       9.6,9.9                                               

  Female                   5.1--10.7     5.6--9.47       5.43,5.8      9.21,9.6                                              

  **Albumin**\             g/dl\         Combined        3.0--7.3      3.7--6.2                           3.6,3.84           6.1,6.2

  Male                     3.0--7.3      3.7--6.2        3.6,3.9       6.1,6.3                                               

  Female                   3.1--6.6      3.6--6.1        3.55,3.83     6.0,6.2                                               

  **Total cholesterol**    mg/dl\        Combined        54.0--242.0   80.4--206.60                       77.0,83.0          201.0,212.0

  Male                     55.0--242.0   78.13--211.75   74.0,82.0     202.25,215.66                                         

  Female                   54.0--235.0   83.6--202.7     78.3,86.0     194.81,210.0                                          

  **Triglycerides**        mg/dl\        Combined        24.0--255.0   36.0--215.6                        35.0,37.4          208.2,221.6

  Male                     24.0--255.0   36.0--221.9     33.66,39.0    213.0,233.84                                          

  Female                   24.0--250     35.3--201.5     34.48,38.0    190.42,216.07                                         

  **Creatinine**\          mg/dl\        Combined        0.16--1.46    0.47--1.12                         0.42,0.50          1.08,1.15

  Male                     0.16--1.46    0.48--1.13      0.38,0.55     1.1,1.15                                              

  Female                   0.18--1.36    0.47--1.09      0.4,0.51      1.01,1.17                                             

  **Urea**\                mg/dl\        Combined        6.0--56.0     11.0--41.0                         10.4,12.0          40.0,43.0

  Male                     8.0--56.0     12.0--43.0      12.0,13.0     40.0,44.0                                             

  Female                   6.0--50.0     10.0--38.7      10.0,11.0     35.03,41.48                                           

  **Uric acid**\           mg/dl\        Combined        1.7--10.0     2.34--6.60                         2.24,2.4           6.5,6.8

  Male                     1.8--10.0     2.7--6.9        2.5,2.8       6.66,7.0                                              

  Female                   1.7--7.3      2.1--5.9        2.0,2.24      5.5,6.39                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------

**ALT**: Alanine aminotransferase; **ALP**: Alkaline phosphatase; **AST**: Aspartate aminotransferase; **CI**: confidence interval; **dl**: Decilitre; **g**: Gram; **GGT**: Gamma glutamyltransferase; **L**: litre; **mg**: Milligram; **RI**: Reference interval; **SGOT**: Serum glutamate oxaloacetate transaminase; **SGPT**: Serum glutamate pyruvate transaminase; **U**: Unit.

Discussion {#sec018}
==========

Nowadays, developing countries like Ethiopia are facing double burden of communicable and non-communicable diseases \[[@pone.0201782.ref015]\]. In this regard, clinical laboratory attempts to play a major role in providing valuable information for prevention, diagnosis and management of life-threatening diseases \[[@pone.0201782.ref002]\]. Ethiopian population depends on western derived RIs for disease diagnosis and management because of lack of locally established RIs. However, a number of studies showed variations between African and western population derived RIs \[[@pone.0201782.ref016]--[@pone.0201782.ref018]\]. Thus, it is required to establish local RIs for adequate medical care and related health issues.

As clearly presented in [Table 4](#pone.0201782.t004){ref-type="table"}, the RIs were different for African and western population; specially, the upper reference limits of the majority of clinical chemistry parameters were higher for healthy African population \[[@pone.0201782.ref016], [@pone.0201782.ref019]--[@pone.0201782.ref022]\] than western population \[[@pone.0201782.ref023]\] (USA and manufacturer represent the western population). In addition, the western study (USA) \[[@pone.0201782.ref023]\] presented a single RI range for both sexes except uric acid. However, the majority of African based studies \[[@pone.0201782.ref019]--[@pone.0201782.ref022]\]reported a separate RIs for males and females. These discrepancies are the cause of misclassifications which may have a negative impact in the diagnosis and management of African population. Furthermore, the inconsistency may affect African population in terms of financial resources and time.

10.1371/journal.pone.0201782.t004

###### Comparison of clinical chemistry parameter RIs of this study against manufacturer ranges and other similar studies.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analytes                         Sex             Current study   Manufacturer   Northwest Ethiopia \[[@pone.0201782.ref016]\]   Southwest Ethiopia \[[@pone.0201782.ref019]\]   Uganda \[[@pone.0201782.ref020]\]   Tanzania \[[@pone.0201782.ref021]\]   Ghana \[[@pone.0201782.ref022]\]   USA \[[@pone.0201782.ref023]\]
  -------------------------------- --------------- --------------- -------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------- ------------------------------------- ---------------------------------- --------------------------------
  **ALT/SGPT (U/L)**               Combined        5.0--39.0       NA             6.0--43.0                                       11.0--54.0                                      6.6--42.8                           7.7--48.3                             7--51                              0--35

  Male                             5.13--42.88     0--42           6.0--44.6      11.2--56.0                                      7.2--43.3                                       9.1--55.                            8--54                                 NA                                 

  Female                           4.3--37.0       0--32           3.0--30.0      10.1--54.0                                      5.3--39.9                                       6.7--44.9                           6--51                                 NA                                 

  **AST/SGOT (U/L)**               Combined        11.0--46.0      NA             9.0--38.0                                       12.0--59.0                                      12.3--34.8                          14.3--48.1                            14--51                             0--35

  Male                             12.13--46.88    0--37           10.5--39.0     13.0--59.5                                      13.2--35.9                                      15.2--53.4                          17--60                                NA                                 

  Female                           10.0--43.8      0--31           6.0--32.1      12.0--59.9                                      11.4--28.8                                      13.5--35.2                          13--48                                NA                                 

  **ALP(U/L)**                     Combined        87.0--451.28    NA             52.4--237.0                                     63.0--376.0                                     44--151                             45.6--158.4                           85--241                            30--120

  Male                             77.2--475.8     80--306         55.3--237.2    55.8--362.9                                     42--159                                         45.4--170.4                         101--353                              NA                                 

  Female                           89.0--381.0     64--306         49.0--236.0    70.4--384.4                                     47--160                                         45.3--155.0                         82--293                               NA                                 

  **Amylase (U/L)**                Combined        29.0--299.0     0--220         48.0--188.8                                     NA                                              45.6--173.6                         42.8--164.4                           32--139                            60--180

  Male                             29.0--309.8     NA              45.3--190.0    NA                                              46--175                                         49.6--180.1                         34--137                               NA                                 

  Female                           29.0--287.9     NA              48.0--187.9    NA                                              44--177                                         41.8--160.4                         30--139                               NA                                 

  **GGT(U/L)**                     Combined        7.0--58.0       9--64          NA                                              NA                                              8.5--68.5                           8.1--107.8                            7--61                              1--94

  Male                             7.0--69.8       NA              NA             NA                                              8.7--70.7                                       9.3--120.8                          9--71                                 NA                                 

  Female                           6.0--39.1       NA              NA             NA                                              8.0--41.3                                       7.3--51.8                           6--53                                 NA                                 

  **Bilirubin (direct) (mg/dl)**   Combined        0.02--0.61      0--0.2         0.01--0.80                                      NA                                              0.02--0.4                           0.04--0.48                            0.05--0.23                         0.1--0.3

  Male                             0.04--0.68      NA              0.02--0.84     NA                                              0.1--0.5                                        0.05--0.49                          0.05--0.24                            NA                                 

  Female                           0.01--0.49      NA              0.01--0.71     NA                                              0.0--0.4                                        0.04--0.34                          0.04--0.22                            NA                                 

  **Bilirubin (total) (mg/dl)**    Combined        0.1--1.1        0.1--1.2       0.26--2.20                                      NA                                              0.4--2.5                            0.30--2.40                            0.17--1.51                         0.3--1.0

  Male                             0.11--1.18      NA              0.27--2.20     NA                                              0.4--2.6                                        0.35--2.46                          0.22--1.87                            NA                                 

  Female                           0.08--0.91      NA              0.21--2.20     NA                                              0.3--1.9                                        0.26--1.83                          0.16--1.56                            NA                                 

  **Total protein (g/dl)**         Combined        5.7--9.6        6.6--8.7       5.3--8.6                                        4.4--11.6                                       6.6--8.9                            6.6--8.5                              5.1--8.7                           5.5--8.0

  Male                             5.7--9.7        NA              5.3--8.7       4.0--11.4                                       6.5--8.9                                        6.7--8.5                            4.7--8.6                              NA                                 

  Female                           5.6--9.47       NA              5.3--8.6       4.6--11.7                                       6.8--9.0                                        6.6--8.6                            5.5--8.7                              NA                                 

  **Albumin (g/dl)**               Combined        3.7--6.2        3.8--5.1       NA                                              NA                                              3.8--5.3                            3.6--5.0                              3.3--5.0                           3.5--5.5

  Male                             3.7--6.2        NA              NA             NA                                              3.9--5.4                                        3.7--5.1                            3.3--5.0                              NA                                 

  Female                           3.6--6.1        NA              NA             NA                                              3.7--5.2                                        3.6--4.9                            3.4--5.0                              NA                                 

  **Total cholesterol (mg/dl)**    Combined        80.4--206.60    0--190         NA                                              55.0--276.0                                     91--233                             95.5--213.8                           77.3--208.1                        \<200

  Male                             78.13--211.75   NA              NA             52.1--252.2                                     90--235                                         89.7--219.3                         69.6--193.3                           NA                                 

  Female                           83.6--202.7     NA              NA             58.0--286.4                                     100--230                                        109--212.7                          81.2--216.6                           NA                                 

  **Triglycerides (mg/dl)**        Combined        36.0--215.6     0--150         NA                                              41.0--264.0                                     39--281                             34.5--255.1                           35.4--194.9                        \<160

  Male                             36.0--221.9     NA              NA             41.3--275.8                                     39--299                                         34.5--266.6                         35.4--194.9                           NA                                 

  Female                           35.3--201.5     NA              NA             41.0--261.2                                     34--206                                         33.7--193.1                         35.4--186                             NA                                 

  **Creatinine (mg/dl)**\          Combined        0.47--1.12      NA             0.23--1.22                                      0.32--1.32                                      0.5--1.2                            0.48--1.02                            0.55--1.33                         \<1.5

  Male                             0.48--1.13      0.6--1.1        0.20--1.29     0.3--1.4                                        0.6--1.2                                        0.54--1.09                          0.63--1.35                            NA                                 

  Female                           0.47--1.09      0.5--0.9        0.25--1.08     0.3--1.3                                        0.5--0.9                                        0.45--0.92                          0.53--1.24                            NA                                 

  **Urea (mg/dl)**                 Combined        11.0--41.0      10--50         NA                                              4.6--35.0                                       9.9--33.2                           9.1--29.5                             5.4--34.2                          21.4--42.9

  Male                             12.0--43.0      NA              NA             4.6--34.5                                       10.1--33.9                                      9.3--29.8                           5.4--37.2                             NA                                 

  Female                           10.0--38.7      NA              NA             4.5--35.8                                       9.4--30.2                                       8.8--27.4                           5.4--32.4                             NA                                 

  **Uric acid (mg/dl)**            Combined        2.34--6.60      NA             NA                                              2.0--7.4                                        3.3--7.8                            2.8--7.5                              1.5--6.7                           NA

  Male                             2.7--6.9        3.4--7.0        NA             2.5--7.9                                        3.5--8.0                                        3.3--7.7                            2.1--7.0                              2.5--8.0                           

  Female                           2.1--5.9        2.4--5.7        NA             2.0--7.2                                        3.0--6.8                                        2.5--6.1                            1.4--6.4                              1.5--6.0                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**ALT**: Alanine aminotransferase; **ALP**: Alkaline phosphatase; **AST**: Aspartate aminotransferase; **CI**: confidence interval; **dl**: Decilitre; **g**: Gram; **GGT**: Gamma glutamyltransferase; **L**: litre; **mg**: Milligram; **NA**: Not available; **SGOT**: Serum glutamate oxaloacetate transaminase; **SGPT**: Serum glutamate pyruvate transaminase; **USA**: United States of America; **U**: Unit.

This study showed that there is a significant difference of clinical chemistry parameter values by sex. All clinical chemistry parameter values were higher among males than females except for total cholesterol; females had higher total cholesterol value than males. Our study findings are consistent with previous reports of other African countries where there were significant differences for the majority of clinical chemistry parameter values by sex although the higher and lower values were different across studies for both sexes \[[@pone.0201782.ref016], [@pone.0201782.ref018], [@pone.0201782.ref024], [@pone.0201782.ref025]\].

There is observable clinical chemistry parameter RIs variation between the current study and studies conducted in northwest Ethiopia \[[@pone.0201782.ref016]\] and southwest Ethiopia \[[@pone.0201782.ref019]\] (Tables [3](#pone.0201782.t003){ref-type="table"} and [4](#pone.0201782.t004){ref-type="table"}). Except for ALT, there are RIs differences between current study and northwest Ethiopian study. Similarly, the RIs of all clinical chemistry parameters established by southwest Ethiopian study don't match with our study. These inconsistencies may be due to demographic differences; in the current study, the majority of the study participants were young adults, but the northwest and southwest Ethiopian studies included participants with wider age range (15 to \>65 years). Geographic (around 800 Kilometers gap between the current and southwest Ethiopian study areas) and ethnic differences may be accountable for the observed variations. In addition, variablity of analysis methods, equipments and reagents being used may affect the value of clinical chemistry parameters in this different studies \[[@pone.0201782.ref010]\].

Clinical chemistry parameter RIs are variable among studies conducted in different countries including our study (Tables [3](#pone.0201782.t003){ref-type="table"} and [4](#pone.0201782.t004){ref-type="table"}, \[[@pone.0201782.ref017], [@pone.0201782.ref026]\]). The ALP, amylase, direct bilirubin, albumin and total protein upper reference limits of the current study are higher than studies done in Uganda \[[@pone.0201782.ref020]\], Tanzania \[[@pone.0201782.ref021]\], Ghana \[[@pone.0201782.ref022]\] and USA \[[@pone.0201782.ref023]\]. On the contrary, the total cholesterol, triglycerides and uric acid upper reference limits of the current study are lower than studies in Uganda, Tanzania and India \[[@pone.0201782.ref020], [@pone.0201782.ref021], [@pone.0201782.ref027]\]. In addition, GGT, total bilirubin and total cholesterol upper reference limits of this study are in line with those from Ghana \[[@pone.0201782.ref022]\]. Ethnic, genetic, demographic, nutritional, cultural, life style, disease distribution, and seasonal differences are important factors which affect the values of clinical laboratory RIs among apparently healthy individuals \[[@pone.0201782.ref027]--[@pone.0201782.ref030]\]. Furthermore, a number of studies and international guidelines recommended that local clinical laboratory RIs should be established for each homogenous population \[[@pone.0201782.ref010], [@pone.0201782.ref031], [@pone.0201782.ref032]\].

This study was limited to young adult blood donors and unable to include children, adolescents and older individuals. Thus, we were not able to confirm whether or not partition among different age groups was needed for clinical chemistry parameter RIs. Dietary pattern of study participants was not assessed because it was difficult to standardize it based on international guidelines. In addition, the resource has limited us to establish the RIs only for routinely requested clinical chemistry parameters in Ethiopian setting.

Conclusion {#sec019}
==========

The established RIs of clinical chemistry parameters are potentially useful in the diagnosis, management and monitoring of disease progression in the study setting. There are significant RIs variations between the current and other Ethiopian studies. Therefore, further local and nationwide studies, including all age and ethnic groups, are recommended to establish local and national RIs for clinical chemistry parameters.

Supporting information {#sec020}
======================

###### "Data set used for analysis" includes data on reference intervals of clinical chemistry parameters.

(XLSX)

###### 

Click here for additional data file.
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ALP

:   Alkaline phosphatase

ALT

:   Alanine aminotransferase

APHI

:   Amhara Public Health Institute

CI

:   Confidence interval

CLSI

:   Clinical Laboratory Standards Institute

EPHI

:   Ethiopian Public Health Institute

ELISA

:   enzyme-linked Immunosorbent assay

GGT

:   Gamma-glutamyl transferase

GLP

:   Good laboratory practice

HBV

:   Hepatitis B virus

HCV

:   Hepatitis C virus

HIV

:   Human immune deficiency virus

IFCC

:   International Federation for Clinical Chemistry

IQC

:   Internal quality control

RI

:   Reference interval

RPR

:   Rapid plasma regain

SGOT

:   Serum glutamate oxaloacetate transaminase

SGPT

:   Serum glutamate pyruvate

SOP

:   Standard operating procedure
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